• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

UTSA student wins American Heart Association fellowship for nanosystems engineering research
(University of Texas at San Antonio) University of Texas at San Antonio biomedical engineering Ph.D. candidate Anand Srinivasan has been awarded a $25,000, one-year doctoral fellowship from the American Heart Association. This highly competitive fellowship provides significant funding to doctoral students to support research and training in cardiovascular and stroke discoveries. Srinivasan will develop a new chip-based platform that can be used to test the effectiveness of drug treatments for infective endocarditis, a dangerous bacterial-fungal infection of the heart's inner lining.
Source: EurekAlert! - Social and Behavioral Science - June 19, 2013 Category: Global & Universal Source Type: news